These findings are confirmed in the blood of patients with MYC+ lymphoma treated with enitociclib and elucidate the mechanism of action of P-TEFb targeting by selective CDK9 inhibition for the treatment of patients with NHL with MYC-driven disease. Here, CDK9 is linked to non-Hodgkin lymphoma.